PharmaTalkRadio

This podcast features a fireside chat between Dr Ira Mellman, PICI and Dr Axel Hoos, Former CEO, Scorpion Therapeutics from the 2026 Immuno-Oncology 360° conference. Drawing on Dr Mellman’s extensive experience and current work at the Parker Institute for Cancer Immunotherapy, this conversation provides: Insight into the scientific and clinical trajectory of immuno-oncology Perspectives on the evolving role of collaboration and innovative partnership models like PICI Discussion of the key opportunities and challenges shaping IO innovation at scale A visionary outlook on what the next chapter of immuno-oncology could look like To learn more about the IO360° Summit, please visit https://www.io360summit.com/

As alternative funding pathways decrease and fewer research grants are administered, the relationship between biotech and academia must shift in order to continue to achieve innovation and development. In this podcast, featuring a panel discussion from the 2026 Chief Medical Officer Summit 360°, CMOs and academics present on these shifts in the global clinical development ecosystem, and how academia and biotech can better partner to develop new therapies for patients, with specific examples. To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com .

This podcast feature a panel discussion from the 2026 Chief Medical Officer Summit 360°, biotech CMOs and executives from CROs and consultancies. Together they discuss how small biotechs can accelerate clinical development with fit-for-purpose global clinical trial strategies. Specifically: The benefits and challenges of running clinical trials in different regions When and at which phases to run clinical trials in different countries Bridging data for approval applications Managing global clinical trials in areas with different cultures and health systems To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com .

This podcast features a panel discussion from the 2026 Chief Medical Officer Summit 360°, with biotech CMOs and representatives from pharma companies. Together, they address how interactions around partnerships or acquisitions differ from those of investment from biotech companies and how CMOs can support those conversations. This includes: How pharma companies analyze potential partners What biotech companies can do to best partner with pharma How the CMO fits into various phases of transactions Appreciating how different c-suite colleagues and direct reports experience these transactions The different pharma teams CMOs will interact with Common challenges to partnerships and how to pre-empt them What happens after the acquisition To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com .

In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays. More specifically, Mike discusses: How Advarra is leveraging past IRB data sources to identify common causes of site burden, study delays and amendments What questions sponsors should be asking of AI vendors, to pick the correct partner How sponsors have responded to the insights surfaced by this technology Why sponsors must adapt to a flexibility mindset in order to truly make changes with downstream impact

Tapping into research-naïve sites offers a strategic opportunity to expand patient access. That’s exactly what Endo did when faced with challenges activating sites for their orthopedic study. This case study shares how Endo enabled a new site through hands-on mentorship, infrastructure support, and trust-building— resulting in sustainable partnerships and broader patient reach. How naïve sites can help address access and enrollment bottlenecks How to support inexperienced sites with the right sponsor-led infrastructure What it takes to shift internal expectations and foster lasting site partnerships Speakers: Carrie Lewis Executive Director, Clinical Program Optimization, Endo Suzy Montayne Site Relationship Manager, Endo Terry Oehler, DPM Founder & CEO, Colorado Clinical Research

AstraZeneca’s US Site Engagement Leads will share how they are reimagining sponsor-site relationships through a trust-first, high-engagement operating model that emphasizes flexibility, responsiveness, and co-creation. This session will showcase how their embedded approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery—backed by real metrics and lessons learned from a three-year initiative. Key topics include: How continuous site feedback loops and flexibility with SOPs improved startup timelines Metrics from a recent study showing impact: 30% faster budget negotiations, 27% reduced activation times, 68% of recruitment from 42% of sites Tools and tactics used to build consistency, transparency, and trust across studies Lessons learned and how the program has scaled globally Speakers: Shannon Edwards Site Engagement Lead, AstraZeneca Tina Nghiem Site Engagement Lead, AstraZeneca

A case study highlighting how Eli Lilly partnered with clinical sites to co-design practical, site-centric solutions that enhanced trial execution and operational efficiency. Fireside Guest: Shafaat Ali Khan Clinical Research Lead (CRL) Director – Investigator Engagement, Eli Lilly & Co Moderator: Jyoti Angal, PhD Director, Clinical Research, Avera McKennan Hospital & University Health Center

This case study highlights how Basil Clinical Research and Takeda’s first-time partnership became the top global recruiter, exceeding enrollment goals by tenfold through proactive assessments, early collaboration, and inclusive design. Learn how Takeda’s shift from transactional to strategic, long-term partnerships made this success possible. Identifying and partnering with highpotential sites Incorporating site feedback and early collaboration to improve trial execution Building trust and fostering long-term site relationships Key actions that led to exceptional enrollment and trial efficiency Speakers: Brandon Doyle, MBA Associate Director, Study Site Engagement, Takeda Mark Rapp, MD Principal Investigator, Basil Clinical Research

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address: Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherence How pharma can use drug delivery device data with predictive analytics to forecast demand and optimize production Enabling patient-centric design and innovation by analyzing device usage data To learn more about the PODD Conference, please visit PODDConference.com .

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically: How pharma and suppliers can improve sustainability Creating designs with lower carbon footprints relative to fabrication and materials Circular recycling models To learn more about the PODD Conference, please visit PODDConference.com .

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives discuss specific examples of AI/ML usage by pharma companies through the combination product development process from iteration to commercialization as well as a discussion on how this field will evolve in the coming years. To learn more about the PODD Conference, please visit PODDConference.com .

Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manufacturing as well as growing pains and lessons learned in scaling. To learn more about the PODD Conference, please visit PODDConference.com .

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss progess in the development of liquid/liquid and liquid/lyo dual chamber systems. Specifically, they address: Overcoming primary container and autoinjector challenges for liquid-liquid delivery Improving upon dual chamber reconstitution devices Finding the right approach to navigate supply chain To learn more about the PODD Conference, please visit PODDConference.com .

About this Podcast: As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma. Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen in terms of pharma companies that are successfully implementing AI across their enterprise, and how he would recommend organizations that are just starting out on their AI journey assess their individual needs and priorities when it comes to AI. More specifically, Sean discusses: Separating short-term, mid-term and long-term costs and benefits of implementing AI What business leaders at JP Morgan Health 2026 were saying about how they view the value of AI AI deployed for bottom-line revenue versus internal team efficiency What the first steps would be for sponsors to successfully integrate AI across their enterprise

About this podcast: Recorded at DPHARM 2025, Bayer's Dr Bernhard Glombitza reports on the development, implementation and early impact of their clinical operations reorgnization. He describes how shifting from a traditional hierarchical model to a network of highly empowered teams reduced management layers, broadening the scope of work and changed cross-country operations monitoring. Dr Glombitza details the results of the change thus far, including significant increases in efficiency and reduction in cost, maintaining quality levels and study targets, and improving employee job satisfaction.

About this podcast: In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact. More specifically, Ms Gershkowitz focuses on: Defining role standards and recruiting the right talent Co-creatin research with patient communities and developing patient-centered outcomes Generating metrics that demonstrate the impact on R&D

When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs address how to develop a balanced strategy that takes into account the ambition to answer these questions with the realities of complicated clinical trials. More specifically: Prioritizing data collection strategy to answer key scientific questions while avoiding overcomplication Designing trials around real patients rather than ideal patients Better understanding the objectives of the study and asking the questions that achieve those objectives Better partnering with patients and PIs To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org .

Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss how they used platform devices in concert with an internal engagement strategy to speed up development. Specifically, they address: Advantages and disadvantages to platform approaches for device development Opportunities to overcome technical limitations Approaches to bring a platform into multiple product design history files Regulatory hurdles Assessing business case and getting organizational buy-in To learn more about the PODD Conference, please visit Drug-Delivery.org .